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ABSTRACT
Objective: Scientific knowledge about symptoms of common mental disorders in elite sports is scarce.
Consequently, the objectives of the study were to (i) establish the 12-month incidence of symptoms of
common mental disorders (CMD; distress, anxiety/depression, sleep disturbance, adverse alcohol use,
eating disorders) among Dutch elite athletes and (ii) explore their potential association with several
stressors (being injured, recent life events, career dissatisfaction).
Methods: A prospective cohort study with a 12-month follow-up period was conducted. The study used
validated questionnaires to assess symptoms of common mental disorders (thus not clinically diag-
nosed) as well as several stressors; an electronic questionnaire was set up and repeatedly distributed.
Results: A total of 203 elite athletes gave their written informed consent to participate in the study,
from which 143 completed the 12-month follow-up period (follow-up rate of 70%). Incidence of
symptoms of CMD ranged from 6% for adverse alcohol use to 57% for symptoms of anxiety/depression.
Over the follow-up period, around 17% of the participants reported two simultaneous symptoms of
CMD, and around 19% reported three simultaneous symptoms of CMD. Inferences between some
stressors and symptoms of CMD were found but none of the associations were statistically significant.
Conclusions: Substantial 12-month incidence rates of symptoms of CMD (self-reported and not
clinically diagnosed) were found among Dutch elite athletes (especially for anxiety/depression), appear-
ing similar to the ones found among athletes from other sports disciplines and the Dutch general
population. Also, inferences between some stressors and symptoms of CMD were found but none of
the associations were statistically significant. Supportive and preventive measures directed towards
symptoms of CMD should be developed to improve awareness and psychological resilience of athletes,
which would likely improve their performance and quality-of-life.
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1. Introduction
Over the past few years, attention to symptoms of distress
(overstressed), anxiety, depression, or adverse substance use –
typically referred as symptoms of common mental disorders
(CMD) – among professional athletes has been growing [1,2].
Among professional footballers (soccer), prevalence of symp-
toms of CMD ranged from 9% for adverse alcohol use to 38%
for anxiety/depression, while 12-month incidence reached up
to 37% for anxiety/depression [3,4]. Among elite Gaelic ath-
letes, prevalence and 6-month incidence reached up to 48 and
21% for anxiety/depression, respectively, while around 24%
reported 2 simultaneous (comorbidity) symptoms of CMD [5].
Among professional rugby players, prevalence of symptoms of
CMD ranged from 15% for adverse alcohol use to 30% for
anxiety/depression, almost 20% of these participants reporting
a comorbidity of two simultaneous symptoms of CMD [6].
Among professional ice hockey players, prevalence of symp-
toms of CMD ranged from 8% for adverse alcohol use to 24%
for anxiety/depression, while 6-month incidence reached up
to 22% for eating disorders [7]. In these aforementioned stu-
dies, the occurrence of symptoms of CMD was shown to be
related with several stressors among which were musculoske-
letal injuries, recent life events, and career dissatisfaction [3–7].
Among Dutch elite athletes, the 4-week prevalence of
symptoms of CMD ranged from 6% for adverse alcohol use
to 45% for anxiety/depression [8]. By contrast to football,
Gaelic sports, rugby and ice hockey, empirical information
collected longitudinally about the incidence (newly devel-
oped) of symptoms of CMD among elite Dutch athletes
drawn from multiple sports is not available yet, while these
symptoms are likely to be associated with similar stressors.
Accordingly, the objectives of the study were to (i) establish
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the 12-month incidence and comorbidity of symptoms of
CMDs (distress, anxiety/depression, sleep disturbance, adverse
alcohol use, eating disorders) among Dutch elite athletes and
(ii) explore their potential association with several stressors
(being injured, recent life events, career dissatisfaction).
2. Methods
2.1. Design
Reported in compliance with the Strengthening the Reporting
of Observational Studies in Epidemiology (STROBE) statement,
the present study was an observational prospective cohort
study with three measurements over a follow-up period of
12 months by means of questionnaires [9]. Ethical approval
was provided by the Medical Ethics Review Committee of the
Academic Medical Center (W15_051#15.0062; Amsterdam, The
Netherlands). The present research was conducted in accor-
dance with the Declaration of Helsinki [10].
2.2. Study setting, participants and sample size
Participants were Dutch elite athletes from the Netherlands
Olympic Committee*Netherlands Sports Confederation
(NOC*NSF). NOC*NSF is the Dutch association which provides
financial, material, performance, and social advice and support
to both current and former elite athletes. Elite athletes from
NOC*NSF are committing significant time to elite sports and
are competing at international or highest national sporting
level (eligible for Olympic Games and national teams competi-
tions). Inclusion criteria for the participants were: (i) being on
the NOC*NSF list of official elite athletes; (ii) being aged
18 years or older; and (iii) being fluent in Dutch. With regard
to the first aim of the study, sample size calculation indicated
that at least 130 athletes were required (power of 80%; con-
fidence interval (CI) of 95%; precision of 5%) under the
assumption that one out of five athletes might suffer from a
symptom of CMD [11]. Expecting a baseline response rate of
around 40% and a loss to follow-up at 50% (based on previous
similar studies in other sports), we intended to invite at least
620 Dutch elite athletes.
2.3. Dependent variables: symptoms of CMDs
Symptoms of distress, anxiety/depression, sleep disturbance,
adverse alcohol use, and eating disorders were measured at
baseline (presence/absence in previous four weeks) and dur-
ing the follow up (presence/absence in previous 6 months).
Distress was measured using the Distress Screener (3 items
scored on a 3-point scale) which is based on the four-dimen-
sional symptom questionnaire (4DSQ) (e.g. ‘Did you recently
suffer from worry?’) [12,13]. The 4DSQ i.e. Distress Screener has
been validated in several languages among which Dutch
(internal consistency: 0.6–0.7; test-retest coefficients: ≥ 0.9;
criterion-related validity: sensitivity 0. 8, specificity 0.7, Area
Under ROC Curve ≥0.8) [12,13]. A total score ranging from 0 to
6 was obtained by summing up the answers on the three
items, a total score of 3 or less indicating the absence of
distress and a total score of 4 or more indicating the presence
of distress [12,13]. The 12-item General Health Questionnaire
(GHQ-12) was used to assess psychological symptoms related
to anxiety/depression (e.g. ‘Have you recently felt under
strain?’) [14]. The GHQ-12 has been validated in several lan-
guages among which Dutch (internal consistency: 0.7–0.9;
criterion-related validity: sensitivity 0.8, specificity 0.8, Area
Under ROC Curve ≥0.8) [14]. Based on the traditional scoring
system, a total score ranging from 0 to 12 was calculated by
summing up the answers on the 12 items, with a score of 2 or
less indicating no signs of anxiety/depression and a score of 3
or more indicating signs of anxiety/depression (Area Under
Curve = 0.9) [14]. Based on the PROMIS (short form), sleep
disturbance was assessed through four single questions (e.g.
‘Did you recently have some problem to sleep?’) scored on a
5-point scale (from ‘not at all’ to ‘very much’) [15]. The PROMIS
has been validated in several languages among which Dutch
(internal consistency: >0.9; construct validity: product-moment
correlations ≥0.9) (for detailed information, see www.nihpro
mis.org). A total score ranging from 1 to 20 is obtained by
summing up the answers to the four questions, a score of 12
or less indicating the absence of sleep disturbance and a score
of 13 or more indicating the presence of sleep disturbance
[15]. Level of alcohol consumption was detected using the 3-
item AUDIT-C (e.g. ‘How many standard drinks containing
alcohol do you have on a typical day?’) [16]. The AUDIT-C
has been validated in several languages among which Dutch
(test-retest coefficients: 0.6–0.9; criterion-related validity: sen-
sitivity 0.8, specificity 0.8, Area Under ROC Curve ≥0.7) [17]. A
total score ranging from 0 to 12 was obtained by summing up
the answers on the three items, a score of 4 or less indicating
the absence of adverse alcohol use, and a score of 5 or more
indicating the presence of adverse alcohol use [16,17]. The
Eating disorder Screen for Primary care (5-items scored as ‘yes’
or ‘no;’ ‘0’ for favorable answer, ‘1’ for unfavorable answer) was
used as a screening instrument to detect eating disorders (e.g.
‘Were you satisfied with your eating patterns?’) [18]. The
Eating disorder Screen for Primary care has been validated in
several languages among which Dutch (criterion-related valid-
ity: sensitivity 1.0, specificity 0.7) [18]. A total score ranging
from 0 to 5 is obtained by summing up the answers on the
five items, a score of 0 or 1 indicating the absence of eating
disorders and a score of 2 or more indicating the presence of
eating disorders [18].
2.4. Independent variables: stressors
Being injured, number of recent life events and career dissa-
tisfaction were measured at baseline (and during follow up).
The presence of musculoskeletal injury was examined through
a single question (yes or no), injury being defined as one that
involved the musculoskeletal system (bone, joint, ligament,
muscles, tendons) and occurred during training or competi-
tion and led to the current training or competition absence
(definition being clearly stated to the participants) [19]. Based
on the validated Social Athletic Readjustment Rating Scale, the
occurrence of life events (e.g. ‘Death of spouse,’ ‘Change in
financial state’) in the previous 6 months was explored by 14
single questions (yes or no) [20]. Score was calculated by
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summing up the life events occurred in the previous 6 months
and the sum score was also subsequently transformed into a
dichotomous variable: not exposed to recent life event, or
exposed to 1 or more recent life events. Elite sport career
dissatisfaction was explored through the validated
Greenhaus scale (e.g. ‘I am satisfied with the success I have
achieved in my career’) (5 items on a 5-point scale) [21]. A total
score (5–25) was obtained by summing up the answers to the
five items and this sum score was also subsequently trans-
formed as a dichotomous variable: 5–12 as being dissatisfied
with elite sport career and 13–25 as being satisfied [21].
2.5. Procedures
Based on the independent and dependent variables included
in the study, a baseline and 2 follow-up electronic anonymous
questionnaires available in Dutch were created
(FluidSurveysTM), including the following descriptive variables:
age, gender, height, weight, type of sport, duration of elite
sport career, educational level, employment or study status,
and number of working or studying hours. In order to guar-
antee the strict confidentiality of the responses, no personal
identifiable information was included in the questionnaires.
Each questionnaire took about 15–20 min to complete.
Information about the purpose and procedures of the study
was sent per email to potential participants by the medical
staff of NOC*NSF. Participants interested in the study, gave
their informed consent and were given access to the baseline
online questionnaire which they were asked to complete
within two weeks. After completion of the baseline question-
naire, participants could give their informed consent for the
follow-up questionnaire and leave therefore their email
address. At 6- and 12-month follow-up, participants were
invited by email to complete the second and third question-
naire within 2 weeks. Reminders at baseline and follow up
were sent after 2 and 4 weeks. Once completed, the electronic
questionnaires were saved automatically on a secured electro-
nic server that only the principal investigator could access.
Participants participated voluntarily in the study and did not
receive any reward for their participation. Baseline question-
naires were distributed online between October and
December 2015.
2.6. Statistical methods
All data analyses were performed using the statistical soft-
ware IBM SPSS Statistics 23.0 for Windows. Descriptive data
analyses (mean, standard deviation, frequency, range) were
performed with the descriptive and independent variables
measured at baseline. To explore whether loss to follow up
was selective, we compared baseline characteristics (age,
height, weight, duration of elite sport career) of nonrespon-
ders and responders at follow up by means of independent
T-tests [11]. The 12-months incidence and comorbidity of
symptoms of CMD in the whole group of participants were
calculated over the follow-up period of 12 months, using the
adjusted Wald method (incidence: sample size of 150 per-
sons or less) for 95% confidence intervals (95% CI) [11].
Incidence (expressed as a percentage) was calculated as
the proportion of the number of participants with a newly
given symptom of CMD during the 12-months follow-up
relative to the total number of players without any symptom
of CMD at baseline [11]. Comorbidity of two, three, four, or
five simultaneous symptoms of CMD was defined as the
simultaneously presence of two, three, four, or five symp-
toms of CMD (respectively) among the participants.
Comorbidity was expressed as a percentage and calculated
as the proportion of the number of participants with newly
developed two, three, four, or five simultaneous symptoms
of CMD during the 12-month follow-up relative to the total
number of players without any symptom of CMD at baseline.
The relative risks (RR) and related 95% CI were calculated to
explore the strength of the association between potential
baseline stressors and the onset of symptoms of CMD
(dichotomous dependent variable) during the subsequent
12-month follow up [11].
3. Results
3.1. Participants
A total of 726 elite athletes were contacted for the study by
NOC*NSF, from which 203 gave their written informed con-
sent to participate in the study (response rate of 28%). After
the follow-up period of 12 months, a total of 143 athletes had
completed the follow up (follow-up rate of 70%). The flow-
chart of the recruitment of the participants is presented in
Figure 1. The mean age of the participants at baseline (36%
male; 64% female) was 27 years (SD = 7), and they had been
active in elite sport for eight years on average (SD = 5; 48% in
team sports; 52% in individual sports). All characteristics of the
participants (total cohort and subgroups) are presented in
Table 1.
3.2. Incidence and comorbidity of symptoms of CMDs
The incidence of symptoms of CMD among Dutch elite ath-
letes over the follow-up period of 12 months ranged from 6%
for adverse alcohol use to 57% for symptoms of anxiety/
depression. Seventeen percent of the participants reported
two simultaneous symptoms of CMD over the follow-up per-
iod, 19% three simultaneous symptoms of CMD and 3% five
simultaneous symptoms of CMD. The 12-month incidence and
comorbidity (and related 95% CI) of symptoms of CMD among
Dutch elite athletes are presented in Table 2.
3.3. Potential association between stressors and
symptoms of CMDs
Some stressors under study inferred with symptoms of CMD.
For instance, being injured inferred with symptoms of distress
(RR = 2.5; 95%CI = 0.2–45.0) while career dissatisfaction
inferred with symptoms of anxiety/depression (RR = 3.5; 95%
CI = 0.4–35.5) and symptoms of adverse alcohol use (RR = 7.0;
95%CI = 0.4–138.2). However, none of the associations was
found to be statistically significant. All RR and related 95%CI
are presented in Table 3.
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4. Discussion
The main findings of this study were that the 12-month inci-
dence of symptoms of CMD among Dutch elite was 32% for
distress, 57% for anxiety/depression, 19% for sleeping distur-
bance, 6% for adverse alcohol use, and 17% for eating dis-
orders. Over the follow-up period, around 17% of the
participants reported two simultaneous symptoms of CMD,
and around 19% reported three simultaneous symptoms of
CMD. Also, inferences between some stressors and symptoms
of CMD were found but none of the associations were statis-
tically significant.
Participants contacted for study 
N = 726 
Participants included at baseline (T0) 
N = 203 (28%) 
Completed questionnaires at follow-up (T1, 6 
months) 
N = 157 (77%) 
N = 46 lost to follow-up 
N = 523 not available  
for study 
Completed questionnaires at follow-up (T2, 12 
months) 
N = 143 (92%) 
N = 14 lost to follow-up 
Figure 1. Flowchart of the recruitment and follow-up of Dutch elite athletes.
Table 1. Baseline characteristics of the Dutch elite athletes.
Total (N = 203) No CMD (N = 74) CMD (N = 129)
Age (in years; mean ± SD) 27 ± 7 26 ± 6 28 ± 8
Male/Female (%) 36/64 38/62 34/66
Height (in cm; mean ± SD) 177 ± 10 179 ± 10 177 ± 10
Weight (in kg; mean ± SD) 71 ± 13 71 ± 13 71 ± 13
Duration of elite sport career (in years; mean ± SD) 8 ± 5 7 ± 5 8 ± 5
Team/Individual sport (%) 48/52 43/57 50/50
Educational level (%)
No schooling completed 2 3 1
Nursery/Elementary school 1 0 2
High school 7 9 6
Vocational/technical school 34 35 32
College, university or equivalent 56 53 59
Currently working or studying (%) 49 50 50
Working/studying hours per week (in hours; mean ± SD) 17 ± 14 18 ± 15 16 ± 13
One or more severe injuries (%) 64 60 65
One or more surgeries (%) 31 26 34
One or more recent life events (%) 72 65 82
Career dissatisfaction (%) 31 18 36
Baseline prevalence (%)
Distress 27
Anxiety/depression 45
Sleep disturbance 22
Adverse alcohol use 6
Eating disorders 32
N: number of participants; no CMD: group without symptoms of common mental disorders at baseline; CMD: group with symptoms of common mental disorders at
baseline; SD: standard deviation; cm: centimeters; kg: kilograms; %: percentage
Table 2. 12-month incidence of symptoms of common mental disorders among
Dutch elite athletes.
Incidence (95% CI)
Distress 32.4 (19.6–48.6)
Anxiety/depression 56.8 (40.9–71.3)
Sleep disturbance 19.4 (9.5–35.3)
Adverse alcohol use 5.6 (0.6–19.1)
Eating disorders 16.7 (7.5–32.3)
Comorbidity – 2 symptoms 16.7 (7.5–32.3)
Comorbidity – 3 symptoms 19.4 (9.5–35.3)
Comorbidity – 4 symptoms 0 (0–8.4)
Comorbidity – 5 symptoms 2.8 (<0.1–15.4)
95% CI: confidence interval
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4.1. Comparisons with athletes from other professional
i.e. elite sports
Several recent studies using similar scales for measuring symp-
toms of CMD that we used in our study were conducted among
athletes across several professional i.e. elite sports. Among
European professional footballers (N = 262) recruited in Finland,
France, Norway, Spain, and Sweden, 12-month incidence rates of
symptoms of CMD ranged from 12% for distress to 37% for
anxiety/depression, while approximately 13%of these participants
reported 2 simultaneous symptoms of CMD [4]. In this study,
professional footballers reporting recent adverse life events or
career dissatisfaction were more likely to report symptoms of
CMD, but statistically significant associations were not found [4].
In Gaelic sports (N = 204), 6-month incidence of symptoms of CMD
ranged from 11% for sleep disturbance to 21% for anxiety/depres-
sion, while severe musculoskeletal injury, recent life events and
career dissatisfaction led to an increased risk for symptoms of CMD
[5]. In South African professional cricket (N = 78), 6-month inci-
dence of symptoms of CMD over the follow-up period ranged
from 9% for distress to 15% for anxiety/depression, sleep distur-
bance, and adverse alcohol use [22]. In professional ice hockey
(N = 81), the incidence of symptoms of CMD over a follow-up
period of 6 months ranged from 6% for distress and adverse
alcohol use to 22% for eating disorders [7]. In this study, profes-
sional ice hockey players exposed to a higher number of recent life
events and/or higher level of career dissatisfaction were found to
be 5 times more likely to report symptoms of CMD by comparison
to those less or unexposed [7]. Despite some trivial differences,
most incidence rates of symptoms of CMD found in our study
among Dutch elite athletes are similar to those found among
professional i.e. elite athletes from other sports disciplines. This
concurswith our expectations as professional i.e. elite athletes, are,
regardless their sport discipline, exposed during their careers to
similar stressors thatmight lead to symptoms of CMD [23,24]. Only
the incidence of symptoms of anxiety/depression is higher than in
other sports. A potential explanation is the gender distribution of
our study population (one-third males and two-thirds females) as
females are more likely to suffer from anxiety/depression than
males [1,2]. Another explanation is that our follow-up study was
conducted in the year of theOlympic Games in Rio (Brazil), such an
important event being more likely to bring to most athletes
anxious moments (qualification or not) and disappointments (no
medals) rather than positive moments. However, such potential
explanation cannot be underpinned by our study.
4.2. Comparisons with the Dutch general population
In the Netherlands, the Mental Health Survey and Incidence
Study (NEMESIS) showed that the 12-month prevalence for
mood, anxiety, and substance use disorders reached up to 10%
[25]. However, a valid comparison of these results with ours
cannot be made because NEMESIS referred to the prevalence
of CMD [25]. Even more, NEMESIS used other instruments (inter-
view, namely the Composite International Diagnostic Interview)
to establish the presence of CMD than those we used in our
study, making any comparison invalid and biased [25].
4.3. Methodological considerations
Four main methodological considerations of the present study
should be mentioned. First, as the recruitment procedures
were blinded to the research team for privacy and confidenti-
ality reasons (participants invited by NOC*NSF), a nonresponse
analysis could not be conducted. Second, participants (as in
any scientific study) were free to be included in the study and
thus self-selected. This might have led to selection bias as
participants with more interest with symptoms of CMD
might have been more likely to participate. Third, the
response rate achieved in our study at baseline (28%) was
lower than expected, while a good follow-up rate (70%) was
secured. The low response rate at baseline might limit the
representativeness of our results, confirming once more that
a study in professional i.e. elite sports about symptoms of
CMD including a large study sample remains challenging to
conduct. Last, the dependent variables in our study were
measured through self-report. Consequently, it is essential to
mention that the occurrence of self-reported symptoms of
CMD was studied but not the presence of clinically diagnosed
CMD. While one might suggest that the validity of self-
reported data might be limited, the importance and relevance
of Patient Reported Outcome Measures (PROMs) studies has
been lately empowered in clinical and sports medicine in
order to assess the aspects that matter most to patients and
to enable important clinical questions to be answered [26].
Also, the self-report instruments used in our study were vali-
dated in Dutch and not too extensive (influencing negatively
internal consistency) in order to secure adherence of the
participants in our study.
4.4. Practical implications
Our study contributes largely to raise self-awareness about
symptoms of CMD in professional, i.e. elite sports as epidemio-
logical information on symptoms of CMD in sports remains
scarce [27]. Contradictory to our a-priori hypotheses, we did
not find any statistically significant association between the
stressors under study and our outcome measures.
Nevertheless, monitoring the occurrence of stressors such as
injuries, life events, or career transitions among elite athletes
Table 3. Association (relative risk and 95% CI) between stressors and symptoms of common mental disorders among Dutch elite athletes.
Distress Anxiety/Depression Sleeping disturbance Adverse alcohol use Eating disorders
Being injures No 1.0 1.0 1.0 1.0 1.0
Yes 2.5 (0.2–45.0) 0.9 (0.5–15.1) n/a n/a n/a
Recent life events No 1.0 1.0 1.0 1.0 1.0
Yes 1.5 (0.2–11.0) 1.1 (0.4–3.3) 0.8 (0.2–3.0) 1.6 (0.2–14.5) 0.9 (0.2–4.6)
Career dissatisfaction No 1.0 1.0 1.0 1.0 1.0
Yes 0.7 (0.2–2.2) 3.5 (0.4–35.5) 1.0 (0.1–10.3) 7.0 (0.4–138.2) 2.2 (0.2–26.3)
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during their sport career should remain one of the priority of the
technical, medical, and psychological/behavioral teams around
the athletes [28,29]. The authors believe that this is even more
important before and after an important event such as the
Olympic Games. Such a monitoring should enable to identify
athletes being predisposed to report symptoms of CMD and
refer them timely to proper medical care and support. Our study
empowers also the current assertive approach of NOC*NSF that
relies on supportive and preventive measures directed toward
symptoms of CMD among Dutch athletes. Such an approach is
key in order to protect the health of elite athletes and empower
their performances as well as their quality of life.
5. Conclusions
Substantial 12-month incidence rates of symptoms of CMD
(self-reported and not clinically diagnosed) were found
among Dutch elite athletes (especially for anxiety/depression),
appearing similar to the ones found among athletes from
other sports disciplines and the Dutch general population.
The occurrence of symptoms of CMD inferred with being
injured, recent life events, and career dissatisfaction but
none of these associations were statistically significant.
Supportive and preventive measures directed toward symp-
toms of CMD should be developed to improve not only
awareness and psychological resilience of athletes but also
their performance and quality of life.
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